Government-Owned Inventions; Availability for Licensing, 11137-11138 [2012-4310]

Download as PDF Federal Register / Vol. 77, No. 37 / Friday, February 24, 2012 / Notices Request for Comments: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Nathaniel Rothman, Senior Investigator for the Occupational and Environmental Epidemiology Branch, Division of Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Room 8118, Rockville, MD 20892 or call non-toll-free number 301– 496–9093 or email your request, including your address to: rothmann @mail.nih.gov. Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. Dated: February 21, 2012. Vivian Horovitch-Kelley, NCI Project Clearance Liaison, National Institutes of Health. [FR Doc. 2012–4347 Filed 2–23–12; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. srobinson on DSK4SPTVN1PROD with NOTICES AGENCY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of SUMMARY: VerDate Mar<15>2010 18:34 Feb 23, 2012 Jkt 226001 federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301– 496–7057; fax: 301–402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. 11137 0—Research Tools. Patent protection is not being pursued for these technologies. Licensing Contact: Suryanarayana (Sury) Vepa, Ph.D., J.D.; 301–435–5020; vepas@mail.nih.gov. Novel Biomarkers for Alcohol-Induced Liver Disease (ALD) Description of Technology: Alcoholinduced liver disease (ALD) is a leading cause of non accident-related deaths worldwide. ALD is reversible if identified in the early stages, but early diagnosis is difficult with existing tools. One problem associated with developing a new diagnostic tool is the genetic background associated heterogeneity in physiological responses Polyclonal Antibodies Useful for the to chronic alcohol consumption. The Detection of Vangl1 and Vangl2 inventors of the present technology have Proteins Which Play a Role in solved this problem and have Developmental Processes discovered background-independent novel biomarkers for ALD. In the Description of Technology: Vangl1 (Van Gogh like 1) and Vangl2 (Van Gogh current studies, the inventors generated two genetically distinct lines of like 2) are two core proteins mediating PPARalpha-null mice and evaluated the establishment of Planar Cell Polarity levels of urine metabolites after alcohol (PCP), which refers to the polarity of exposure. The inventors have identified epithelial cells within a plane indole-3-lactic acid and phenyllactic orthogonal to their apical-basal axis. Disruption of core PCP proteins leads to acid as putative biomarkers for ALD. Indole-3-lactic acid and phenyllactic many developmental defects, including acid levels were significantly elevated open neural tube, misorientation of in both lines of PPARalpha-null mice sensory hair cells in the inner ear, after two to three months of alcohol polycystic kidney disease and skeletal administration. The inventors had deformations. In humans, mutations in Vangl1 and Vangl2 have been identified identified indole-3-lactic acid and phenyllactic acid to be background in patients with neural tube defects, independent markers for ALD. such as spina bifida, the most common Potential Commercial Applications: permanently disabling birth defect in Useful for early non-invasive screening the United States. NHGRI researchers of ALD in large numbers of subjects have recently generated rabbit irrespective of their genetic background. polyclonal antibodies against Vangl1 Competitive Advantages: and phosphorylated Vangl2 proteins • Easily adaptable for the that are suitable for endogenous Vangl1 development of highly sensitive and Vangl2 detection. spectroscopy-based assay kits. Potential Commercial Applications: • Amenable for the development of Anti-Vangl1 and Vangl2 antibodies high-throughput mass spectrometric could be used in the development of analysis of urine samples to detect early diagnostic and therapeutic treatments onset of ALD. for PCP-related developmental defects. Development Stage: Development Stage: • Early-stage. • Pre-clinical. • Pre-clinical. • In vitro data available. • In vivo data available (animal). Inventors: Yingzi Yang and Bo Gao Inventors: Soumen Kanti Manna and (NHGRI); Yingzi Yang and Hai Song Frank J. Gonzalez (NCI). (NHGRI). Publications: Publications: 1. Manna SK, et al. UPLC–MS-based 1. Gao B, et al. Wnt signaling urine metabolomics reveals indole-3gradients establish planar cell polarity lactic acid and phenyllactic acid as by inducing Vangl2 phosphorylation conserved biomarkers for alcoholthrough Ror2. Dev Cell. 2011 Feb induced liver disease in the Ppara-null 15;20(2):163–176. [PMID 21316585] mouse model. J Proteome Res. 2011 Sep 2. Song H, et al. Planar cell polarity breaks bilateral symmetry by controlling 2;10(9):4120–4133. [PMID 21749142] 2. Manna SK, et al. Identification of ciliary positioning. Nature. 2010 Jul 15;466(7304):378–382. [PMID 20562861] noninvasive biomarkers for alcoholinduced liver disease using urinary Intellectual Property: HHS Reference metabolomics and the Ppara-null Nos. E–135–2011/0 and E–136–2011/ PO 00000 Frm 00075 Fmt 4703 Sfmt 4703 E:\FR\FM\24FEN1.SGM 24FEN1 11138 Federal Register / Vol. 77, No. 37 / Friday, February 24, 2012 / Notices mouse. J Proteome Res. 2010 Aug 6;9(8):4176–4188. [PMID 20540569] Intellectual Property: HHS Reference No. E–172–2011/0—U.S. Provisional Application No. 61/507,573 filed 13 Jul 2011. Licensing Contact: Suryanarayana (Sury) Vepa, Ph.D., J.D.; 301–435–5020; vepas@mail.nih.gov. srobinson on DSK4SPTVN1PROD with NOTICES Biomarkers for Niemann-Pick Disease Type C and Related Disorders of Oxysterol Accumulation Description of Technology: NiemannPick disease type C (NPC) is a lethal lysosomal storage disorder characterized by liver disease and progressive neurodegeneration. Lysosomal storage is impaired by oxidized cholesterol (oxysterol) accumulation. Presenting signs and symptoms are nonspecific, and the diagnosis is frequently difficult and delayed. The inventors established a rapid ELISA assay to evaluate biomarker levels in serum. The ELISA assay tests a novel combination of two biomarkers significantly elevated in NPC patients, Cathepsin D and Galectin3. Other diseases can cause oxysterol accumulation, including other lysosomal storage diseases, cholesterol trafficking diseases, and neurodegenerative diseases. At least for the lysosomal storage diseases, the combination of elevated Cathepsin D and Galectin-3 appears specific for NPC. Cathepsin D is a lysosomal enzyme involved in protein degradation. The secreted Galectin-3 is mostly known as a chemoattractant for immune cells. Potential Commercial Applications: • NPC diagnosis. • NPC patient disease progression monitoring. • NPC therapeutic efficacy testing in Clinical Trials. • Application of above methods to related diseases. Competitive Advantages: • Fast and non-invasive ELISA serum assay. • Potential for high sensitivity. • Cost effective. Development Stage: • Pilot. • Early-stage. • In vivo data available (animal). • In vivo data available (human). Inventor: Forbes D. Porter (NICHD). Intellectual Property: HHS Reference No. E–302–2011/0—U.S. Provisional Application No. 61/576,062 filed 15 Dec 2011. Licensing Contact: Betty B. Tong, Ph.D.; 301–594–6565; tongb@mail.nih.gov. VerDate Mar<15>2010 18:34 Feb 23, 2012 Jkt 226001 Dated: February 21, 2012. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2012–4310 Filed 2–23–12; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Shared High End Instrumentation: NMR and X-ray. Date: March 13–14, 2012. Time: 7 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: Kathryn M Koeller, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4166, MSC 7806, Bethesda, MD 20892, 301–435– 2681, koellerk@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Hematology. Date: March 13–14, 2012. Time: 11:30 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: Bukhtiar H Shah, DVM, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4120, MSC 7802, Bethesda, MD 20892, (301) 301 806–7314, shahb@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; P 41 Competitive Revision. Date: March 14, 2012. Time: 11 a.m. to 4 p.m. Agenda: To review and evaluate grant applications. PO 00000 Frm 00076 Fmt 4703 Sfmt 4703 Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: Khalid Masood, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5120, MSC 7854, Bethesda, MD 20892, 301–435– 2392, masoodk@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Basic and Integrative Bioengineering. Date: March 21, 2012. Time: 11 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: General Services Administration (GSA), 301 7th Street SW., 1511, Washington, DC 20407. Contact Person: Ross D. Shonat, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6172, MSC 7892, Bethesda, MD 20892, 301–435– 2786, ross.shonat@nih.hhs.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR10–225: Program Project: Center for Macromolecular Modeling and Bioinformatics. Date: March 21–23, 2012. Time: 7 p.m. to 12 p.m. Agenda: To review and evaluate grant applications. Place: University of Illinois at UrbanaChampaign, Urbana-Champaign, IL. Contact Person: Nitsa Rosenzweig, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1102, MSC 7760, Bethesda, MD 20892, (301) 435– 1747, rosenzweign@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA Panel: Developmental System Biology. Date: March 22–23, 2012. Time: 8 a.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: Raya Mandler, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5217, MSC 7840, Bethesda, MD 20892, 301–402– 8228, rayam@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Basic and Integrative Bioengineering. Date: March 22, 2012. Time: 11 a.m. to 9 p.m. Agenda: To review and evaluate grant applications. Place: General Services Administration, Washington DC, 301 7th Street SW., 1511, Washington, DC 20407. Contact Person: David R Filpula, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6181, MSC 7892, Bethesda, MD 20892, 301–435– 2902, filpuladr@mail.nih.gov. E:\FR\FM\24FEN1.SGM 24FEN1

Agencies

[Federal Register Volume 77, Number 37 (Friday, February 24, 2012)]
[Notices]
[Pages 11137-11138]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-4310]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Polyclonal Antibodies Useful for the Detection of Vangl1 and Vangl2 
Proteins Which Play a Role in Developmental Processes

    Description of Technology: Vangl1 (Van Gogh like 1) and Vangl2 (Van 
Gogh like 2) are two core proteins mediating establishment of Planar 
Cell Polarity (PCP), which refers to the polarity of epithelial cells 
within a plane orthogonal to their apical-basal axis. Disruption of 
core PCP proteins leads to many developmental defects, including open 
neural tube, misorientation of sensory hair cells in the inner ear, 
polycystic kidney disease and skeletal deformations. In humans, 
mutations in Vangl1 and Vangl2 have been identified in patients with 
neural tube defects, such as spina bifida, the most common permanently 
disabling birth defect in the United States. NHGRI researchers have 
recently generated rabbit polyclonal antibodies against Vangl1 and 
phosphorylated Vangl2 proteins that are suitable for endogenous Vangl1 
and Vangl2 detection.
    Potential Commercial Applications: Anti-Vangl1 and Vangl2 
antibodies could be used in the development of diagnostic and 
therapeutic treatments for PCP-related developmental defects.
    Development Stage:
     Pre-clinical.
     In vitro data available.
    Inventors: Yingzi Yang and Bo Gao (NHGRI); Yingzi Yang and Hai Song 
(NHGRI).
    Publications:
    1. Gao B, et al. Wnt signaling gradients establish planar cell 
polarity by inducing Vangl2 phosphorylation through Ror2. Dev Cell. 
2011 Feb 15;20(2):163-176. [PMID 21316585]
    2. Song H, et al. Planar cell polarity breaks bilateral symmetry by 
controlling ciliary positioning. Nature. 2010 Jul 15;466(7304):378-382. 
[PMID 20562861]
    Intellectual Property: HHS Reference Nos. E-135-2011/0 and E-136-
2011/0--Research Tools. Patent protection is not being pursued for 
these technologies.
    Licensing Contact: Suryanarayana (Sury) Vepa, Ph.D., J.D.; 301-435-
5020; vepas@mail.nih.gov.

Novel Biomarkers for Alcohol-Induced Liver Disease (ALD)

    Description of Technology: Alcohol-induced liver disease (ALD) is a 
leading cause of non accident-related deaths worldwide. ALD is 
reversible if identified in the early stages, but early diagnosis is 
difficult with existing tools. One problem associated with developing a 
new diagnostic tool is the genetic background associated heterogeneity 
in physiological responses to chronic alcohol consumption. The 
inventors of the present technology have solved this problem and have 
discovered background-independent novel biomarkers for ALD. In the 
current studies, the inventors generated two genetically distinct lines 
of PPARalpha-null mice and evaluated the levels of urine metabolites 
after alcohol exposure. The inventors have identified indole-3-lactic 
acid and phenyllactic acid as putative biomarkers for ALD. Indole-3-
lactic acid and phenyllactic acid levels were significantly elevated in 
both lines of PPARalpha-null mice after two to three months of alcohol 
administration. The inventors had identified indole-3-lactic acid and 
phenyllactic acid to be background independent markers for ALD.
    Potential Commercial Applications: Useful for early non-invasive 
screening of ALD in large numbers of subjects irrespective of their 
genetic background.
    Competitive Advantages:
     Easily adaptable for the development of highly sensitive 
spectroscopy-based assay kits.
     Amenable for the development of high-throughput mass 
spectrometric analysis of urine samples to detect early onset of ALD.
    Development Stage:
     Early-stage.
     Pre-clinical.
     In vivo data available (animal).
    Inventors: Soumen Kanti Manna and Frank J. Gonzalez (NCI).
    Publications:
    1. Manna SK, et al. UPLC-MS-based urine metabolomics reveals 
indole-3-lactic acid and phenyllactic acid as conserved biomarkers for 
alcohol-induced liver disease in the Ppara-null mouse model. J Proteome 
Res. 2011 Sep 2;10(9):4120-4133. [PMID 21749142]
    2. Manna SK, et al. Identification of noninvasive biomarkers for 
alcohol-induced liver disease using urinary metabolomics and the Ppara-
null

[[Page 11138]]

mouse. J Proteome Res. 2010 Aug 6;9(8):4176-4188. [PMID 20540569]
    Intellectual Property: HHS Reference No. E-172-2011/0--U.S. 
Provisional Application No. 61/507,573 filed 13 Jul 2011.
    Licensing Contact: Suryanarayana (Sury) Vepa, Ph.D., J.D.; 301-435-
5020; vepas@mail.nih.gov.

Biomarkers for Niemann-Pick Disease Type C and Related Disorders of 
Oxysterol Accumulation

    Description of Technology: Niemann-Pick disease type C (NPC) is a 
lethal lysosomal storage disorder characterized by liver disease and 
progressive neurodegeneration. Lysosomal storage is impaired by 
oxidized cholesterol (oxysterol) accumulation. Presenting signs and 
symptoms are nonspecific, and the diagnosis is frequently difficult and 
delayed. The inventors established a rapid ELISA assay to evaluate 
biomarker levels in serum. The ELISA assay tests a novel combination of 
two biomarkers significantly elevated in NPC patients, Cathepsin D and 
Galectin-3. Other diseases can cause oxysterol accumulation, including 
other lysosomal storage diseases, cholesterol trafficking diseases, and 
neurodegenerative diseases. At least for the lysosomal storage 
diseases, the combination of elevated Cathepsin D and Galectin-3 
appears specific for NPC. Cathepsin D is a lysosomal enzyme involved in 
protein degradation. The secreted Galectin-3 is mostly known as a 
chemoattractant for immune cells.
    Potential Commercial Applications:
     NPC diagnosis.
     NPC patient disease progression monitoring.
     NPC therapeutic efficacy testing in Clinical Trials.
     Application of above methods to related diseases.
    Competitive Advantages:
     Fast and non-invasive ELISA serum assay.
     Potential for high sensitivity.
     Cost effective.
    Development Stage:
     Pilot.
     Early-stage.
     In vivo data available (animal).
     In vivo data available (human).
    Inventor: Forbes D. Porter (NICHD).
    Intellectual Property: HHS Reference No. E-302-2011/0--U.S. 
Provisional Application No. 61/576,062 filed 15 Dec 2011.
    Licensing Contact: Betty B. Tong, Ph.D.; 301-594-6565; 
tongb@mail.nih.gov.

     Dated: February 21, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2012-4310 Filed 2-23-12; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.